UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of
1934

       Date of Report (Date of Earliest Event Reported): March 17, 2009

                        Commission File Number 000-52263


                              CAVIT SCIENCES, INC.
             (Exact name of registrant as specified in its charter)

           Florida                                              03-
0586935
  (State or Other Jurisdiction                               (I.R.S
Employer
of Incorporation or Organization)
Identification Number)

                                  27 1st Avenue
                           Paterson, New Jersey 07514
                    (Address of principal executive offices)

                                 (973) 278-7327
              (Registrant's telephone number, including area code)


                      1600 South Dixie Highway, Suite 500,
                           Boca Raton , Florida 33432
                                (Former address)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under
any of the
following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities
Act (17
    CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17
    CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
    Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
    Exchange Act (17 CFR 240.13e-4(c))

<PAGE>

ITEM 5.02 DEPARTURE OF CERTAIN OFFICERS; APPOINTMENT OF CERTAIN
OFFICERS

Mr. Colm J. King on March 17, 2009 resigned from the board of
directors of Cavit Sciences. The  Board of Directors has not decided on
a successor for this position.

     As  previously  reported,  on  October  6,  2008,  the  Board of
Directors
appointed Ms. Margaret Smyth to serve as a Director. Effective
immediately after
the filing of this  Current  Report,  Ms.  Smyth will become the
Interim  Chief
Executive Officer of Cavit Sciences, Inc.

     Ms. Smyth will succeed Colm J. King who served as our  President
and Chief
Executive  Officer  since  April  2006.  Mr. King  unilaterally
terminated  his
employment agreement with Cavit Sciences,  Inc. effective November 14,
2008. Mr.
King will continue to serve as a member of our Board of Directors.

     Ms. Smyth is the Vice  President  of  Operations  of Falcon East
Inc.,  the
largest  importer/manufacturer of fabric, fabric covered wood and
matting to the
picture  framing  industry on the East  Coast.  Aside from daily
management  of
office personnel and shipping/receiving, operations also include weekly
payroll,
inventory/ordering, warehousing, distribution and fulfillment.

     On  November  10,  2008,  Matthew J.  Cohen  resigned  from his
consulting
position  as Chief  Financial  Officer  of Cavit  Sciences,  Inc.  The
Board of
Directors has not decided on a successor for this position.

ITEM 8.01 OTHER EVENTS

     Effective with the filing of this Current report, Cavit Sciences,
Inc. will
relocate our principal  administrative  offices and warehouse facility
to 27 1st
Avenue,  Paterson,  New Jersey  07514.  Our new  telephone  number will
be (973)
278-7327.

                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of
1934, the
Registrant  has duly  caused  this  report  to be  signed  on its
behalf by the
undersigned thereunto authorized.

Date: March 17, 2009                Cavit Sciences, Inc.


                                       By: /s/ Maggie Smyth
                                           ----------------------------
---------
                                           Maggie Smyth
                                           President and Chief
Executive Officer

                                       2
[{"type": "8-K", "sequence": "1", "filename": "k8032709.txt", "secsgml_size_bytes": 4140}]
{"company-data": {"conformed-name": "Cavit Sciences, Inc.", "cik": "0001368502", "assigned-sic": "2834", "irs-number": "030586935", "state-of-incorporation": "FL", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-52263", "film-number": "09708866"}, "business-address": {"street1": "27 1ST AVE", "city": "PATERSON", "state": "NJ", "zip": "07514", "phone": "973-278-7327"}, "mail-address": {"street1": "P.O. BOX 222", "city": "OAK GROVE", "state": "MO", "zip": "64075"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of
1934

       Date of Report (Date of Earliest Event Reported): March 17, 2009

                        Commission File Number 000-52263

                              CAVIT SCIENCES, INC.
             (Exact name of registrant as specified in its charter)

           Florida                                              03-
0586935
  (State or Other Jurisdiction                               (I.R.S
Employer
of Incorporation or Organization)
Identification Number)

                                  27 1st Avenue
                           Paterson, New Jersey 07514
                    (Address of principal executive offices)

                                 (973) 278-7327
              (Registrant's telephone number, including area code)

                      1600 South Dixie Highway, Suite 500,
                           Boca Raton , Florida 33432
                                (Former address)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under
any of the
following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities
Act (17
    CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17
    CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
    Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
    Exchange Act (17 CFR 240.13e-4(c))
ITEM 5.02 DEPARTURE OF CERTAIN OFFICERS; APPOINTMENT OF CERTAIN
OFFICERS

Mr. Colm J. King on March 17, 2009 resigned from the board of
directors of Cavit Sciences. The  Board of Directors has not decided on
a successor for this position.

     As  previously  reported,  on  October  6,  2008,  the  Board of
Directors
appointed Ms. Margaret Smyth to serve as a Director. Effective
immediately after
the filing of this  Current  Report,  Ms.  Smyth will become the
Interim  Chief
Executive Officer of Cavit Sciences, Inc.

     Ms. Smyth will succeed Colm J. King who served as our  President
and Chief
Executive  Officer  since  April  2006.  Mr. King  unilaterally
terminated  his
employment agreement with Cavit Sciences,  Inc. effective November 14,
2008. Mr.
King will continue to serve as a member of our Board of Directors.

     Ms. Smyth is the Vice  President  of  Operations  of Falcon East
Inc.,  the
largest  importer/manufacturer of fabric, fabric covered wood and
matting to the
picture  framing  industry on the East  Coast.  Aside from daily
management  of
office personnel and shipping/receiving, operations also include weekly
payroll,
inventory/ordering, warehousing, distribution and fulfillment.

     On  November  10,  2008,  Matthew J.  Cohen  resigned  from his
consulting
position  as Chief  Financial  Officer  of Cavit  Sciences,  Inc.  The
Board of
Directors has not decided on a successor for this position.

ITEM 8.01 OTHER EVENTS

     Effective with the filing of this Current report, Cavit Sciences,
Inc. will
relocate our principal  administrative  offices and warehouse facility
to 27 1st
Avenue,  Paterson,  New Jersey  07514.  Our new  telephone  number will
be (973)
278-7327.

                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of
1934, the
Registrant  has duly  caused  this  report  to be  signed  on its
behalf by the
undersigned thereunto authorized.

Date: March 17, 2009                Cavit Sciences, Inc.

                                       By: /s/ Maggie Smyth
                                           ----------------------------
---------
                                           Maggie Smyth
                                           President and Chief
Executive Officer

                                       2